3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.

Article Details

Citation
Copy to clipboard

Vu AT, Cohn ST, Terefenko EA, Moore WJ, Zhang P, Mahaney PE, Trybulski EJ, Goljer I, Dooley R, Bray JA, Johnston GH, Leiter J, Deecher DC

3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.

Bioorg Med Chem Lett. 2009 May 1;19(9):2464-7. doi: 10.1016/j.bmcl.2009.03.054. Epub 2009 Mar 18.

PubMed ID
19329313 [ View in PubMed
]
Abstract

A series of 3-(arylamino)-3-phenylpropan-2-olamines was prepared and screened for their ability to inhibit monoamine reuptake. A number of analogues displayed significant dual norepinephrine and serotonin reuptake inhibition. Compounds in this class exhibited minimal affinity for the dopamine transporter.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
AtomoxetineSodium-dependent noradrenaline transporterIC 50 (nM)3N/AN/ADetails
AtomoxetineSodium-dependent serotonin transporterIC 50 (nM)48N/AN/ADetails
DesipramineSodium-dependent noradrenaline transporterIC 50 (nM)3.4N/AN/ADetails
DuloxetineSodium-dependent noradrenaline transporterIC 50 (nM)4N/AN/ADetails
DuloxetineSodium-dependent serotonin transporterIC 50 (nM)3N/AN/ADetails
FluoxetineSodium-dependent serotonin transporterIC 50 (nM)10N/AN/ADetails
MazindolSodium-dependent dopamine transporterIC 50 (nM)22N/AN/ADetails